welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).

expertly curated content related to this topic
-
Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous PolyposisSulindac sulfone (Exisulind), a metaboli...
-
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisBACKGROUND : Patients with familial aden...
-
8 Myths About Ostomies DebunkedMore than 750,000 Americans live with an...
-
Bonnies Diary March 08https://jtvcancersupport.com/embed/46053...
-
Ileal Pouch-Anal Anastomosis: Points of ControversyRestorative proctocolectomy with ileal p...
-
Anorectal Functional Outcome After Repeated Transanal Endoscopic MicrosurgeryAIM : To evaluate the status of anorecta...
-
Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)The goal of this research study is to te...